Get started

Smallcaps

GGG.V -- Air filtration equipment to fight spread of virusesPulled out of overbought area and filled the gap. Fib. support at .09. Strong volume. I am in at .09. --------------------------------------------------------------------------------------------------------------------------- G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19 April 1, 2020 - TheNewswire - Ronkonkoma, NY USA - G6 Materials Corp (the "Company" or "G6," (TSXV:GGG) (OTC:GPHBF) is pleased to provide an update from its Research & Development department. The outbreak of the COVID-19 has drastically altered the economic landscape, and G6 management is optimizing the business model to accommodate the new reality, addressing these new business opportunities. The CEO of the Company, Daniel Stolyarov, explains, “There is an imminent demand for solutions that allow for the removal of viruses from the air and surfaces increasing the safety of the immediate environment. The Company has prioritized work in this sector and plans to address these market needs immediately.” The Company's Research & Development Department has developed a solution for air purification products that are designed to mitigate the threat of virus infection in confined spaces such as offices and industrial warehouses. There is substantial scientific evidence of antiviral and antibacterial effectiveness of graphene coatings. The Company has found a unique method to incorporate graphene in the air filtration systems making them more efficient in killing germs. The Company is currently conducting internal testing, and will subsequently apply for appropriate accreditations. The applications of this solution are numerous. Such systems can be included in existing HVAC systems or included in the design of new ones. They can be combined with conventional filtration methods as well as UV irradiation. Any large scale structures, including office buildings and factories, could all be the benefactor of this system. Stolyarov continues, “Economies all around the world are experiencing unprecedented disruption due to the COVID-19 situation, leaving a long-lasting impact. We hope that the quarantine measures prove effective in stemming the spread of the virus, but quarantines cannot last forever. When people return to work they will demand that their work environment is safe. We provide a solution to this problem". The Company will continue testing of the prototypes and is actively looking for an industrial partner to rapidly expand the manufacturing capability and bring these highly demanded products to market.
TSXV:GGG
by wealth_bakery
VS.C -- eSports and Video Streaming Rewards PlatformVS.C is approaching the eSports sector the right way with its proprietary rewards platform that integrates into applications, games and streaming services. This is one of the sectors that is thriving during the coronavirus pandemic. The company keeps delivering on growth and has just announced an expansion into streaming video via Kast. Haywood analyst gives it a BUY rating with a .55 price target. Technically, the stock has been heavily accumulated in recent months. The selldown in the last few days was likely a short attack targeting the .185 - .195 gap. It failed but I used it as an opportunity to build a position at .22 average. Given the string of positive news releases and the extension of the .40 warrants that was just announced, I expect that the company will make a promotional push to try and get them exercised. But even without promo, the stock should be trading a fair bit higher based on the business growth/expansion. It's one of those rare times when I do agree with the institutional analysts.
VLong
by wealth_bakery
1
IPA.V - Agreement with Johnson & Johnson for Coronavirus vaccineIPA.V appears to have entered into agreement with Johnson & Johnson's subsidiary to develop the Coronavirus vaccine. The market is asleep due to cryptically worded news release. Connecting the dots... --------------------------------------------------------------------------------------------------------------------------------------- ImmunoPrecise Announces Agreement with Janssen VICTORIA and CAMBRIDGE, MA, April 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed. "This Agreement validates Talem's business concept in early antibody discovery and development," said Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Scientific Director at IPA Europe. "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications." "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America," added Jennifer Bath, President and CEO of IPA. --------------------------------------------------------------------------------------------------------------------------------------- The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine. That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other firms have. The deal was signed with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) on March 27, 2020. It followed another order, made as part of the same contract with Janssen, for $150 million on March 20, 2020, for a “new antiviral” for COVID-19. A spokesperson from Johnson & Johnson didn’t provide any more details on the specific order, but confirmed the $456 million award related to a collaboration with ASPR’s Biomedical Advanced Research and Development Authority (BARDA), as announced in February. That work was built on previous contracts for developing countermeasures for other influenzas. The value of the coronavirus-specific work hadn’t previously been revealed and is the largest known contract for a coronavirus vaccine to date. It forms part of a deal between the U.S. government and Johnson & Johnson to co-invest $1 billion into vaccine research, development and clinical testing. The company says it now expects human clinical studies for its vaccine candidate to go ahead, at the latest, by September 2020. It anticipates the first batches of vaccine to be available for emergency use in early 2021.
ILong
by wealth_bakery
1
GSI.V Video systems for smart cities; essential business statusStrong accumulation. Bullish MACD cross. Bullish Stoch/RSI action. I am in at .15. --------------------------------------------------------------------------------------------------------------------- Gatekeeper Operating as Essential Business During COVID-19 Outbreak Abbotsford, BC - TheNewswire - April 6, 2020 - Gatekeeper Systems Inc. (‘Gatekeeper’ or the ‘Company’) (TSXV:GSI) (OTC:GKPRF) (FSE:1GK) a leading provider of intelligent video solutions for public transport and smart cities, provides a corporate update relating to its operations during the COVID-19 outbreak. Gatekeeper, through its subsidiary Gatekeeper Systems USA Inc., has been deemed an essential business during the emergency order which temporarily prohibits operation of non-essential businesses in Pennsylvania. The Company’s business relating to the Southeastern Pennsylvania Transportation Authority (SEPTA) continues normal operations. SEPTA is the Company’s largest customer and represented approximately 30% of the Company’s revenues during its 2019 fiscal year. The Company reports no material change in its contract with SEPTA announced on October 17, 2019 to provide annually recurring services valued at approximately $2.36 million per year. The Company reports no material change in its contract with SEPTA announced on October 9, 2019 to supply and install digital video recorders on SEPTA vehicles and trains in a contract valued at approximately $6.3 million. This contract is expected to be billed during the second half of the Company’s fiscal year which ends August 31, 2020. Gatekeeper has adjusted its business operations during the COVID-19 outbreak to firstly ensure the safety of its employees as its top priority. Protection procedures for service technicians have been implemented and office employees are working from home where possible. The Company is also working with its suppliers and customers during this period of business disruption to ensure continuity of business operations where possible. The Company will report its financial results for its second quarter ended Feb 29, 2020 by the prescribed filing due date of April 29, 2020. Gatekeeper also announces that it has granted an aggregate of 675,000 incentive stock options to certain directors, officers, employees and consultants under the Company’s stock option plan, subject to regulatory approval. The stock options are exercisable at a price of $0.135 for a period of five years from the date of grant and subject to vesting provisions.
TSXV:GSILong
by wealth_bakery
Careful of Getting Sucked into Value Traps!One of the biggest questions after a correction like we just had is: What to buy on the rebound? Lots of stocks are trying to bounce, but which are more likely to perform the best? Longer-term charts can help answer the question. Let’s compare two very different corners of the market: The Nasdaq-100 (QQQ) and the Russell 2000 (IWM). QQQ barely hit a new 52-week low when the market crashed recently. Its trough of $164.93 matched prices from January 30, 2019. IWM , on the other hand, fell to its lowest level in more than four years – all the way down to $95.69. The higher low shows QQQ has more positive investor sentiment. IWM’s lower low shows just the opposite. Small caps (along with energy) were lagging before the coronavirus. They then fell much more when the market crashed. The moral of the story is that charts work. Never ignore underperformance or a lack of new highs. These simple technical indicators speak volumes about the underlying fundamentals. Speaking of fundamentals, did you know less than 20 percent of IWM’s portfolio is in the technology sector? It’s overweight industrials, which took a beating when coronavirus shut down the global economy. QQQ, on the other hand, is officially 44 percent technology. When you include “communication” companies like Alphabet and Facebook , it’s over 50 percent. Throw in Amazon.com (consumer discretionary) and it’s more like 59 percent. There are two takeaways. First, simple chart patterns like highs and lows tell us a lot about fundamentals. They’re also more fun to read than analyst reports. Second, just because something’s bouncing a lot doesn’t mean it will keep outperforming. In the case of IWM, the sharp rebound may be little more than a dead-cat bounce. It might seem counter-intuitive, but often the stocks that fall the least in a correction rise the most after. Disciplined trend followers stick with these patterns to avoid getting sucked into value traps.
NASDAQ:QQQLong
by TradeStation
TTD.V -- Medical supplies 3D printing services; CoronaVirus hypeTTD.V is cheap at $3.5M mkt cap and is joining the CoronaVirus hype train with today's news: Tinkerine Studios in Collaboration with Medical Community produces critically needed 3D Printed Products for COVID-19 ---------------------------------------------------------------------------------------------------------------------------------------------------- March 23, 2020 – TheNewswire - Tinkerine™ Studios Ltd. (TSXV:TTD) ("Tinkerine" or the "Company") announces that with extensive input from medical doctors, general practitioners, emergency responders, nurses, and pharmacists, the Company’s Applied Design Staff has initiated the design and 3D printing of the following devices: 1.Face Shield --Tinkerine now has a working prototype that was printed using its DittoPro 3D printers. The Face Shield will be presented immediately to regional health authorities. Tinkerine’s Face Shield has received strong input from members of the health community to ensure proper fit and protection for users. The face shield is a prototype design; 2.Ventilator 4-way Splitter --Tinkerine and outside parties are currently designing a 4-way splitter that can be used in emergency situations to provide additional capacity for ventilators. Considerations include cross contamination and a one-way check valve to ensure safety. The 4-way splitter is in early stage and is a prototype design; 3.Medical Use Goggles --Input from regional health members resulted in recognizing current and future demand for medical goggles for use in hospitals and other medical facilities. Tinkerine is determining needs based on input from medical professionals and will initiate design ASAP. Tinkerine is also reaching out to its community of teachers and educational professionals to utilize their school districts and post-secondary institutions’ Tinkerine 3D printers. Tinkerine products are in use in 45% of all school districts in its home province of British Columbia. The Company is getting assistance from its Education Advisory Board and Teacher User Group, to create a collaborative pool of 3D Printers to produce greater volumes of medical products and supplies that are in scarce supply. Through this collaboration Tinkerine is working to deploy between 500-1000 additional 3D printers in order to address the COVID-19 healthcare crisis. In the meantime, Tinkerine has initiated discussions with National Resource Council Canada about additional expansion opportunities. The Tinkerine team wants to thank all of the participating healthcare professionals for their assistance and would like to encourage additional members of the medical community to contact our offices about critical products that may be produced using 3D printers. We also want to express our appreciation to all medical and emergency staff for their tireless and selfless efforts to keep us all safe and healthy.
T
by wealth_bakery
3
AGN.C -- Coronavirus Treatment Spec; Phase 2 Clinical Trial newsAnother CoronaVirus spec play. Pulled back from recent highs and trading in the support band, for now. I bought in at .20 - .21 today. $18M mkt cap. 90M float. Could see a nice run on today's news: Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 clinical trial of Ifenprodil for coronavirus patients. The investigators were identified after Algernon retained Novotech to conduct a feasibility study in South Korea. Novotech was asked to advise on the most efficient regulatory approach to initiating a phase 2 clinical trial for Ifenprodil for COVID-19 and to also help identify potential investigators. Ifenprodil is an already approved drug in South Korea and Japan for certain neurological conditions with a known safety history. Algernon has been investigating Ifenprodil under its re-purposed drug program and has appointed Novotech as the lead CRO for its upcoming idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 clinical trial to be conducted in Australia. The Company is in the process of refining the protocol for the phase 2 coronavirus study after receiving input from the investigators, and is working with Novotech to provide the necessary information and support in order to assist with the study’s approval. The study approval process may be expedited due to the current global health crisis. The Company will release more information about the planned phase 2 coronavirus study shortly. The decision to retain Novotech to conduct a feasibility study was made after a recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. “This independent study data, along with the data generated from the Company’s animal studies on IPF and chronic cough, have supported the Company’s recent new COVID-19 and acute lung injury clinical program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
CSE:AGNLong
by wealth_bakery
LBL.V -- Stem cell based CoronaVirus treatment; VOLUME!LBL.V is hitting highest volume on TSX-V today. Very similar setup to VXL.V from last week, just before it made the big move from .14 to .325 but cheaper and much better financials. Cash flow positive. $8.4M market cap. 93M shares out. See the most recent news release with regards to positive outcomes in applying their technology to treat the Coronavirus patients in China: "Recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia." Google "Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease"
LLong
by wealth_bakery
1
Diary | 3/2/2020 | RUT SpreadJustification: Directional Play: Yes, establishing long delta position to reduce short delta and margin. Technical: Below October low. If/Then: Take profit? 50% of credit received. Where will you hedge? $1410 Strategy Details: Short and Long leg: $1410, $1395 Short Leg Delta: 0.16 Expiration: March 6 Disclaimer: This is a page where I look to share knowledge and keep track of trades. If questions, concerns, or suggestions, feel free to comment. I think everyone can improve (myself especially), so if you see something wrong, speak up.
TVC:RUT
by Physik
YouGov - Correction over, new highs expected.Buy YouGov (YOU.L) YouGov plc is a United Kingdom-based international data and analytics company. The Company’s suite of products and services is made up of syndicated data products including YouGov BrandIndex and YouGov Profiles and data services including YouGov Omnibus and YouGovCustom Research. YouGov BrandIndex is a daily brand perception tracker. YouGov Profiles is its planning and segmentation tool. YouGov Omnibus finds out people's opinions, attitudes and behaviors. YouGov Custom Research conducts quantitative and qualitative research. The company has 35 offices in 22 countries. Market Cap: £546Million YouGov is trading in a fantastic long-term uptrend. The shares have recently corrected from fresh all-time highs at 616p and appear to have found some support at the uptrend support line. The shares are on the move higher today, the close above the 10EMA could be a sign that the corrective move lower has come to an end and that further upside can be expected over the medium to long term. We are targeting a move to fresh all-time highs at 700p. Stop: 504p Target: 700p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
LSE:YOULong
by Investamate
AXM.V -- $47M mcap play with a proven $900M+ GOLD depositAXM.V should be on the radar of every #gold investor. $47M mcap company with NI-43-101 compliant resource worth $700M+ USD in the Central African Republic and other promising projects in Africa. Rapidly improving security situation and recently announced strategic partner point to a major opportunity, imo. Bullish MACD cross on the daily chart, bullish RSI/Stochastic following a gap up on the Strategic Partnership LOI announcement. The line "First Strategic Partner" in the latest news release seems to indicate that more material developments are on the way.
ALong
by wealth_bakery
1
EW.V -- Low risk bottom fishing opp; trading at cash valueAn incredible opportunity to buy EW.V at cash value. With JV partner in Romania covering 100% of the exploration costs, this could become a multi-bagger if any of the wells being tested are deemed commercial. EW.V is getting 15% of any oil that spuds. The stock has found a bottom at .055 in the past 2 weeks with bid support steadily increasing. Bullish divergence with MACD/RSI/Stochastic indicators points to a likely near-term breakout. I am long at .055 - .065. ASSETS Cash: $3,719,020 GST Receivable: $7,923 Amounts Receivable: $223,772 Prepaid Expenses: $22,654 Investments: $554,709 Assets Held For Sale: $2,067,867 Total Assets: $6,595,945 LIABILITIES Accounts Payable: $206,404 Decommissioning Liability: $309,904 Liabilities On Asset Held For Sale: $943,472 Deposit: $65,505 Total Liabilities: $1,525,285 NAV $6,595,945 - $1,525,285 = $5,070,660
TSXV:EWLong
by wealth_bakery
ESPT.V On Watch for Downtrend Pattern Breakout (eSports/Gaming)ESPT.V lit up a nice green candle on the daily chart to end the week. Poked its head above the downtrend channel that started on Aug 20th for the first time. The company is one of the early movers in the rapidly growing #eSports sector and is expected to close a revenue-generating acquisition within 1 - 2 weeks, followed by another major acquisition. Both were paid in .30 shares. Currently trading at .225. Very bullish macro environment. Latest RBC Wealth Management report shows #Gaming #eSports sectors are in the early bull cycle. ESPT.V is one of the better values with $2.3M in revenues last year, $9M mkt cap and 43M float. Catchy ticker name is a bonus. :)
ELong
by wealth_bakery
KEW.TO -- Oversold Bounce Play, High Risk / High Reward ScenarioKEW.TO has been selling off as it ran into financial disclosure issues and had to fire a CFO, however the company owns valuable assets, generates revenue and is working with creditors to resolve short term liquidity issues. Definitely high risk/high reward scenario and a tight stop loss is prudent imo. After multiple days of relentless selling, the stock appears to have found a bottom in the mid .70s, reversed and closed at .90, forming a hammer candle on the Daily Chart. Bullish MACD cross on the hourly and Accum/Dist has reversed sharply. Very tight float at 14M means it can move sharply both up and down. If momentum reverses there's very little resistance until 1.50 - 2.00 area. Company issuing an update to re-assure investors could go a long way but news may not come until after New Year.
KLong
by wealth_bakery
1